E-Cigarette Poisoning Cases Among Malaysian Children

Industry Insight by 2FIRSTS.ai
Nov.30.2023
E-Cigarette Poisoning Cases Among Malaysian Children
The Malaysian Ministry of Health revealed that there have been 100 cases of poisoning caused by e-cigarettes from 2015 to August 2020, with 69 cases involving children.

According to a recent report by Nanyang Post, Malaysia's Deputy Minister of Health, Dr. Logunisman, has disclosed that there have been a total of 100 cases of poisoning caused by e-cigarettes from 2015 to August 2020. What is even more alarming is that a staggering 69 cases involve children.

 

In recent years, the hazards of e-cigarettes have raised significant concerns in society. Particularly, children, the most vulnerable group, have become the primary victims in the wave of poisoning cases caused by e-cigarettes.

 

Domestic and international studies have shown that the high concentration of nicotine and other harmful substances in e-cigarette liquids may have serious effects on children's health. The announcement by the Deputy Minister of Health provides stronger legal grounds and social pressure for preventing e-cigarette poisoning and addressing the issue of e-cigarettes.

 

During a session in the parliament, lawmaker Ruganiisman addressed the issue of e-cigarette poisoning incidents raised by opposition party member Lingeswaran. Ruganiisman clarified that the Ministry of Health has presented the "2023 Public Health Tobacco and Smoking Control Bill" to empower the government in regulating the buying and selling of e-cigarettes in the market.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem Drops Texas Lawsuit and Plans to Refile in D.C. Over FDA Handling of Zone Application
Fontem US, the maker and seller of Zone nicotine pouches, has voluntarily dismissed its lawsuit against the U.S. Food and Drug Administration, which it had accused of unfairly delaying its market application.
Mar.25 by 2FIRSTS.ai
STMA Issues Trial Credit Management Rules for E-Cigarette Manufacturers and Wholesalers
STMA Issues Trial Credit Management Rules for E-Cigarette Manufacturers and Wholesalers
Mar.26 by 2FIRSTS.ai
Tennessee House Advances Bill to Direct Vape Tax Revenue to Youth Nicotine Prevention
Tennessee House Advances Bill to Direct Vape Tax Revenue to Youth Nicotine Prevention
The Tennessee House of Representatives advanced legislation this week aimed at curbing underage use of vapor products. House Bill 2360 would allocate 30% of tax revenue from vapor products to counties to support youth nicotine prevention programs across the state.
Mar.23 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11